NEK2 and triple-negative breast carcinoma: Recently, Lee et al. demonstrated that targeting NEK2 with siRNA worked synergistically with paclitaxel and doxorubicin by promoting apoptosis in triple-negative breast cancer cells, thereby enhancing anticancer chemotherapy sensitivity [28].